Anil Tulpule

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman et al. · The Lancet Oncology · 2010 · 853 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells.

Gerald Batist, Anil Tulpule, Birandra K. Sinha et al. · Journal of Biological Chemistry · 1986 · 792 citations · Full text

Medicine, Cancer Biology, Oncology +12

Low-Dose Compared with Standard-Dose m-BACOD Chemotherapy for Non-Hodgkin's Lymphoma Associated with Human Immunodeficiency Virus Infection

Lawrence D. Kaplan, David J. Straus, Marcia A. Testa et al. · New England Journal of Medicine · 1997 · 378 citations · Full text

Medicine, Hematology, Oncology +17

Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

Katherine Robinson, Michael E. Williams, Richard H. van der Jagt et al. · Journal of Clinical Oncology · 2008 · 352 citations

Medicine, Pharmacology, Pharmacotherapy +13

Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats.

Kenneth H. Cowan, Gerald Batist, Anil Tulpule et al. · Proceedings of the National Academy of Sciences · 1986 · 297 citations · Full text

Medicine, Oncology, Pharmacology +14